Many neuropsychiatric disorders such as Parkinson’s, Alzheimer’s and Multiple sclerosis lead to neuroinflammation. The current treatments for Multiple sclerosis largely focus on slowing the progression of the disease and managing symptoms rather than targeting the underlying cause.  

Insights on the neurodegeneration mechanisms of these diseases could lead to the discovery of novel therapeutic targets and reshape how therapies address neuroinflammation.  

Eli Lilly aims to promote innovative research and development efforts that have the potential to significantly advance our understanding of these complex conditions and pave the way for novel therapeutic interventions. We are particularly focused on the immune cells and target identification.